In vivo validation of drugs against COVID-19 (IVADAC).

IVADAC is a joint project (consortium) with Fraunhofer IME ScreeningPort, which is active in the field of pharmaceutical drug discovery. At BNITM, we plan to establish different mouse infection models to evaluate the in vivo efficacy of the newly identified IME compounds against SARS-CoV-2. These include a mouse model of the human immune system (HIS-NSG-A2) and a model expressing human ACE2 - the entry receptor for many coronaviruses such as SARS-CoV-1 and SARS-CoV-2. In addition, we will use comprehensive data analysis to identify new promising drug combinations. After in vitro validation, these drug combinations will in turn be evaluated in our in vivo models.

Project Coordinator: Estefania Rodríguez-Burgos (Department of Virology)